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AKTIVITI PERENCATAN NEURAMINIDASE DAN ANTI SELESEMA 
A(H1N1) SECARA IN VITRO BRUCEA JAVANICA (L.) MERR 
 
ABSTRAK 
 
Wabak virus selesema A (H1N1 and H5N1) telah menimbulkan kebimbangan global 
terhadap risiko pandemik di masa akan datang. Oseltamivir, perencat neuraminidase 
semasa , tidak dapat memenuhi permintaan jika terdapat wabak utama. Oleh itu, terdapat 
keperluan untuk mencari rawatan alternatif untuk influenza  A. Kerja pendokan molekul 
ke atas neuraminidase telah membawa kepada pemilihan tumbuhan untuk dikaji iaitu, 
Brucea javanica (L.) Merr (Simaroubaceae). Objektif kajian ini adalah untuk 
menentukan perencatan neuraminidase dan menentukan secara in vitro aktiviti antivirus 
influenza A Brucea javanica (L.) Merr. Dalam usaha untuk mendapatkan maklumat 
mengenai sebatian aktif daripada tumbuhan ini, buah-buahan kering telah diekstrak 
dengan menggunakan metanol dan difraksinasi menggunakan n-heksana, etil asetat dan 
n-butanol. Satu sebatian telah diasingkan daripada fraksi etil asetat, yang dikenalpasti 
sebagai β-sitosterol 3-O-β-D-glukopiranosida atau daukosterol. Ekstrak mentah metanol, 
fraksi n-heksan, fraksi etil asetat, fraksi n-butanol serta daukosterol telah tertakluk 
kepada asai perencatan neuraminidase (asai MUNANA) terhadap Clostridium 
perfringens, H5N1 dan H1N1 enzim neuraminidase dan asai antivirus in vitro terhadap 
virus A/Indonesia/Unair/2011 (H1N1) pada sel-sel MDCK. Pengurangan titer 
hemaglutinin telah dijalankan menggunakan asai penghemaglutinan (HA), manakala 
pengurangan titer jangkitan virus dijalankan menggunakan asai setengah Dos Jangkitan 
Kultur Tisu (TCID50). Fraksi etil asetat menunjukkan perencatan  yang paling tinggi 
terhadap Clostridium perfringens neuraminidase, dengan IC50 sebanyak 136,46 μg / mL, 
xx 
 
dan fraksi n-heksana mengurangkan titer hemagglutinin hampir sifar dalam asai 
penghemagglutinan. Manakala, daukosterol telah mengurangkan 99.9% titer jangkitan  
virus H1N1 dan menunjukkan aktiviti perencatan tertinggi terhadap neuraminidase 
H1N1 dan neuraminidase H5N1 masing-masing dengan  IC50 117.45 μg/mL dan 148.93 
μg/mL. Menariknya, struktur kimia daukosterol adalah berbeza dengan perencat 
neuraminidase biasa, yang lazimnya dibangunkan berdasarkan analog-analog asid sialik. 
Oleh itu, pendokan molekul (Autodock 3.0.5) telah dijalankan untuk menentukan 
interaksi daukosterol pada tapak pengikat H1N1 neuraminidase (id PDB: 3TI6). 
Keputusan ini telah menunjukkan bahawa daukosterol mempunyai keafinan ikatan yang 
baik pada neuraminidase H1N1 dengan tenaga pengikat bebas yang rendah (ΔG = - 
15,29 kkal / mol). Kesimpulannya, Brucea javanica (L.) Merr mempunyai aktiviti 
perencatan virus berpotensi, bukan sahaja dengan menghalang virus neuraminidase 
tetapi juga oleh dengan merencat aktiviti penghemagglutinan virus dan mengganggu 
replikasi virus pada sel MDCK. 
Kata Kunci : Brucea javanica (L.) Merr, Selesema A, Daukosterol, Assai MUNANA, 
Assai HA, TCID50, Pendokan Molekul. 
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NEURAMINIDASE INHIBITION AND IN VITRO ANTI INFLUENZA A(H1N1) 
ACTIVITIES OF BRUCEA JAVANICA (L.) MERR 
 
ABSTRACT 
 
The outbreak of influenza A viruses (H1N1 and H5N1) has raised a global 
concern on the future risk of a pandemic. Oseltamivir, the current neuraminidase 
inhibitor, could not meet the demand if there is a major outbreak. Thus, there is a need to 
find alternative treatment for influenza A. Our molecular docking work on 
neuraminidase has led to the selection of plant to be studied, Brucea javanica (L.) Merr 
(Simaroubaceae). The objectives of this study were to determine the neuraminidase 
inhibition and in vitro influenza A antiviral activities of Brucea javanica (L.) Merr. In 
order to obtain information about the active compounds from this plant, the dried fruits 
were extracted using methanol, and fractionated using n-hexane, ethyl acetate and n-
butanol.  One compound was isolated from ethyl acetate fraction, identified as β-
sitosterol 3-O-β-D-glucopyranoside or daucosterol. Crude methanol extract, n-hexane 
fraction, ethyl acetate fraction, n-butanol fraction as well as daucosterol were subjected 
to the neuraminidase inhibition assay (MUNANA Assay) against Clostridium 
perfringens, H5N1 and H1N1 neuraminidase enzymes and in vitro antiviral assay 
against A/Indonesia/Unair/2011 (H1N1) virus on MDCK cells. The reduction of 
hemagglutinin titre was performed in hemagglutination assay (HA Assay), while the 
reduction of virus infectious titre was performed in Half Tissue Culture Infectious Dose 
(TCID50) assay. The ethyl acetate fraction showed highest inhibition towards 
Clostridium perfringens neuraminidase, with IC50 of 136.46 µg/mL and n-Hexane 
xxii 
 
fraction reduced the hemagglutinin titre near to zero in hemagglutination assay. Whilst 
daucosterol has shown to reduce 99.9 % of H1N1 virus infectious titre and exhibited the 
highest inhibition activity against H1N1 and H5N1 neuraminidases with IC50 of 117.45 
µg/mL and 148.93 µg/mL, respectively. Interestingly, the chemical structure of 
daucosterol is different with the common neuraminidase inhibitors, which are usually 
based on sialic acid analogues. Thus, molecular docking (Autodock 3.0.5) was carried 
out in order to determine the interaction of daucosterol on the binding site of H1N1 
neuraminidase (PDB id: 3TI6). The result indicated that daucosterol has good binding 
affinity with H1N1 neuraminidase with low free energy of binding (ΔG = - 15.29 
kcal/mol). In conclusion, Brucea javanica (L.) Merr has a promising viral inhibition 
activity, not only by inhibiting viral neuraminidase but also by inhibiting the viral 
hemagglutination activities and interfere to the viral replication on MDCK cell.  
 
Keywords: Brucea javanica (L.) Merr, daucosterol, influenza A, MUNANA assay, HA 
assay, TCID50, Molecular Docking. 
 
 
 
 
1 
 
CHAPTER ONE 
INTRODUCTION 
 
1.1 Statement of Problem  
In April 2009, the World Health Organization (WHO) announced global 
pandemic of new strain of influenza A virus called „swine flu‟ pandemic. It spread 
rapidly all over the world, causing hundreds of more reported cases within days. The 
new variant has been identified as originating of H1N1 form of swine influenza origin 
(S-OIV in short), a progeny strain that caused the huge and deadly flu pandemic in 
1918-1920 (WHO, 2009a).  
 
This was the first global influenza pandemic during 41 years. Starting from 
1918-1919, the Spanish flu that similar with 2009 H1N1 infecting 5% of world 
population causing 20-50 millions of death, the Asian flu (H2N2) (1957-1958) causing 
1- 4 millions deaths and in 1968, the Hongkong flu (H3N2) also causing 1- 4 millions 
deaths worldwide (Ebrahim, 2010).  
 
In addition, the novel swine (H1N1) 2009 virus began spreading globally with 
unpredicted speed that WHO increased its pandemic alert phase from Phase 4 to Phase 5 
on 29 April 2009. On 11 June 2009, the pandemic level was increased further from 
phase 5 to 6, the highest level, which has made the health authorities aware of its future 
potentials as the killer disease (WHO, 2009a). 
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As 1st August 2010, there were over then 18,449 deaths in more than 214 
countries that have reported laboratory confirmed cases of pandemic influenza H1N1 
2009, for the period April 2009 to August 2010. However, WHO stated that the total 
deaths (including unreported deaths) from the H1N1 strain were actually higher (WHO, 
2010a). In fact, Dawood (2012) reported that the estimated global deaths associated with 
H1N1 pandemic 2009 influenza were 15 times higher, which were 284,400 deaths 
(Dawood et al., 2012).  
 
Even in 10 August 2010, WHO has announced that the world were in post 
pandemic, it did not mean that the virus has moved out. The rapid change of the genetic 
mutation of the virus is expected to continue to circulate into seasonal influenza and 
cause another pandemic in the future. It is also feared that another high mortality causing 
virus might arise at anytime (WHO, 2010b). Two years after the post pandemic was 
announced, there are still sporadic cases reported. In August 2012, during weeks 30 to 
31 (22 July 2012 to 4 August 2012), WHO reported that from 67 countries, there were 
2,168 influenza cases, 8.5 % of them (172) related to influenza A (H1N1) pandemic 
2009 virus (WHO, 2012). 
 
Influenza is one of severe viral infections which is highly transmittable affecting 
severe upper respiratory illness, causes substantial morbidity and mortality (Zhang et al., 
2008; Sundarajan et al., 2010). This virus belongs to Orthomyxoviridae family of RNA 
viruses, which divided into A, B and C types. Type A is more virulent then other 
influenza virus B and C. Among of them, only influenza virus A and B seem like 
pathogen to human life while influenza virus C has never been considered causing a 
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large-scale epidemic. The common species which are infected by Influenza A are avian, 
swine, equine, pigs, horse and human. Influenza B and C are mostly found in humans, 
even though a few evidence showed the ability of these virus infect to humans (Gong et 
al., 2007; von Itzstein, 2007). 
 
Fortunately the majority of 2009 influenza A viruses were sensitive to 
oseltamivir, the current neuraminidase inhibitor that has been approved by FDA. 
However, as the frequent change of antigenic character of virus is emerging fast, some 
drug resistance strains are now beginning to develop. In 15 December 2010, WHO 
reported that more than 314 cases of oseltamivir resistant virus carrying the H275Y 
substitution have been detected worldwide (WHO, 2009a). At the end of 2011, there 
were 29 cases of oseltamivir resistant carrying H275Y neuraminidase substitution 
reported in Australia (Hurt et al., 2011). 
 
The existed vaccines against seasonal influenza virus to control this disease have 
been ineffective due to its rapid variable mutation (Kim et al., 2003a; Zhang et al., 
2008). In the period of pandemic, vaccine supplies would not be adequate (Moscona, 
2005).   Thus, the development of effective and safe anti-influenza becomes a matter of 
certainty in drug discovery (Zhang et al., 2008; Gong et al., 2007). 
 
Our work on virtual screening of natural plant compounds toward neuraminidase 
enzyme resulted plant species to be studied. In this study, 3000 natural compounds in 
NADI database were screened by molecular docking using Autodock 3.0.5 software. 
The natural compounds were docked rapidly to the neuraminidase enzyme (PDB id: 
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3B7E). The top 100 compounds were ranked by the lowest energy binding affinity of the 
ligand to the protein binding site and compliance to Lipinski‟s rule of five (drug 
likeness) i.e hydrogen bond donors less than 5, hydrogen bond acceptor less than 10, 
molecular weight less than 500 g/mol, and a partition coefficient less than 5 (Lipinski et 
al., 1997). The top 100 of compounds were clustered according to the plants from where 
the reported compounds have been isolated. One of the plants that contain compounds 
which were predicted to be active inhibiting neuraminidase enzyme was Brucea 
javanica L. (Merr) (Unpublished paper of Prof. Habibah A.Wahab). 
 
1.2 H1N1 virus 
1.2.1 Definition 
Influenza viruses are negative segmented strand RNA, divided in types A, B and 
C, with only type A and B causing severe disease. The virus types can be classified for 
their antigenic characteristics of the core protein. One of virus that belongs to type A 
virus is H1N1. The H1N1 influenza virus (family: Orthomyxoviridae) commonly called 
“swine flu” is a strain of virus made up of swine, human and avian genes, and 
preferentially infects younger people with no or lack of immunity (Kiely et al., 2009). 
Influenza A often causes a global pandemic, while influenza B and C only causes 
regional and local endemic (Alexander and Brown, 2000).  
 
The H1N1 pandemic 2009 virus contains arrangement of gene segments of 
human, swine and avian influenza viruses. The repeated chance of interspecies contact 
between swine, human and bird lead to materialize evolution of new genetic mutation to 
“avian-like” and “human-like” swine lineages (Naffakh and van der Werf, 2009). The 
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unique genetic combination is leading to the possibility of increased human-to-human 
transmission of H1N1 virus. 
 
1.2.2 Anatomy of the Virus 
The influenza A virus looks like a sphere, round or oval shape, with many spikes 
and mushroom shape object on its surface and approximately 90 nm in diameter. The A 
influenza virus containing two functional surface glycoproteins: hemagglutinin (HA) 
and neuraminidase (NA) and also transmembrane proteins: M2 channels (WHO, 1980; 
Wei et al., 2006). Refer to Figure 1.1, the spikes-shaped is known as hemagglutinin 
(HA) and the mushroom-shaped is considered as neuraminidase (NA). Both of them 
recognized the same host cell in the host respiratory membrane, sialic acid, that contains 
proteins with enzymatic functions that are needed for genome replication (Oxford and 
Lambkin, 1998). 
 
In 1980, virologist announced a simple formula for identifying influenza A virus, 
HxNy (x for the molecule type of HA, and y for the molecule type of NA). H1N1 is 
influenza A virus with hemagglutinin molecule type 1 and neuraminidase molecule type 
1 (WHO, 1980). So far, there are 16 different molecules of HA and 9 different 
molecules of NA have been identified (Liu et al., 2009a). The schematic diagram of 
influenza A virus was represented in Figure 1.1. 
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Figure 1.1 Schematic diagram of influenza A virus  
 
1.2.2.1 Neuraminidase (NA) 
A neuraminidase enzyme is a large family, found in a range of organisms. The 
scientists have found nine different types of NA, (N1-N9) but only N1 and N2 are 
important in human infection, while seven additional of NAs  are infected only in 
animals. Neuraminidase is the major protein surface of influenza virus which acts 
extracellularly by cleaving the terminal neuraminic acid from cellular receptors 
recognized by HA.  Based on phylogenetic studies, influenza virus neuraminidase has 
been divided into two groups. Group one contains N1, N4, N5 and N8, and the other 
group contains N2, N3, N6, N7 and N9 (Gong et al., 2007). Neuraminidase plays an 
important role in the pathogenesis of virus infection.  It is facilitating the release of 
newly formed virions from the host cell surface to the neighbourhood cells. By 
removing terminal sialic acid of receptor of the virus, NA acts as a receptor destroying 
enzyme in influenza virus (Clercq, 2006; Lew et al., 2000). 
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The function of NA is to facilitate the mobility of the virus from the site of 
infection. It catalyzes the cleavage of α (2,6)- or α (2,3)-ketosidic linkage between a 
terminal sialic acid and inward-face sugar residue. This broken bond facilitates to spread 
the virus in the respiratory tract and allows elution of progeny virus from the infected 
cells. Lastly, this enzyme will prevent viral inactivation and stimulate viral penetration 
into respiratory epithelial cells (Gong et al., 2007). 
  
1.2.2.2 Active Site of Neuraminidase   
The discovery of three-dimensional structure of influenza neuraminidase in the 
early 1990 provides a tremendous prospect for drug design. There are eight amino acids 
of the active site which are group as basic residues (Arg118, Arg292, Arg371), acidic 
residue (Glu119, Glu227) and hydrophobic residues (Arg152, Trp178, Ile222) with kind 
of amino acid as mentioned in parentheses. These amino acids make direct contact with 
N-Acetylneuraminic acid (Neu5Ac), sialic acid and its derivatives at the distinct 
adjoining pockets. The active site is highly conserved and provides a rigid catalytic 
centre, with the presence of some highly specific hydrophobic area (Gong et al., 2007; 
von Itzstein, 2007). 
 
It is well understood that the structure of NA complexed with Neu5Ac is mainly 
conserved by the charge-charge interaction between the carboxyl group and the pocket 
of three positively charge arginine residues (Arg118, Arg292, Arg371). The NH group 
of 5-N acetyl interacts with the floor of the active site cavity via hydrogen bonding with 
water molecule while the oxygen of the same group is bonded to N of Arg152 via 
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hydrogen bonding. The methyl group is attracted to the hydrophobic pocket near Ile222 
and Trp178 while the two hydroxyl groups of glycerol side chain are bonded to 
carboxylateoxygens of Glu276. The 4-hydroxyl is directly in contact with carboxylate 
oxygen of Glu119 and the glycosidic oxygen interacts with carboxylate oxygen of 
Asp151 (Varghese, 1999; von Itzstein, 2007). The complex structure between 
neuraminidase and sialic acid is presented in Figure 1.2. 
 
 
 
 
 
 
 
Figure 1.2 Complex structure of NA (Shown in surface representation) and sialic acid 
(in stick representation)(Kim et al., 1999). 
 
 
The X-ray crystallographic study reveals that influenza A virus of the group 1-
NA contains a larger cavity neighbouring to the active site, formed by residue 147-152 
(150-loop) which is not found in the group 2-NAs. This cavity creates a much fewer 
polar environments, making it possible to hold the hydrophobic moiety of an inhibitor 
molecule. The group1-NAs can bind ligands in open conformation as well as in the 
 
Arg371 
 
Arg118 
Arg292 
Pocket 3 
Pocket 2 
Pocket 1 
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closed one. There is only closed conformational state found in the group 2-NAs. The 
flexible 150-loop residues are occupied on the area and interact mostly with the amino 
and acetamido groups of oseltamivir moiety. The active sites are still conserved at the 
triad amino acid residues, arginine triad (Arg118, Arg292, and Arg371) that interact 
with carboxylate groups. Moreover, the affinity is increased by the interaction between 
acetamido group and Glu276 that forms hydrogen bonds with the substrate of hydroxyl 
groups (Collins et al., 2008; Rungrotmongkol et al., 2009b).  
Figure 1.3 shows the interaction of oseltamivir with active sites of 
neuraminidase. Green dashed arrows showed H-bonds between oseltamivir and amino 
acid residues of NA (Rungrotmongkol et al., 2009a). 
 
 
 
Figure 1.3 The interactions of oseltamivir active metabolite with the active site of 
neuraminidase. Green dashed arrows showed H-bonds between oseltamivir and amino 
acid residues of NA (Rungrotmongkol et al., 2009b). 
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1.2.2.3 Hemagglutinin (HA) 
Hemaggglutinin (HA) is the spike shaped glycoprotein (refer to Figure 2.1). HA 
of influenza virus has a special role in virus entry. In the first initializing of virus 
infection to respiratory tract, HA mediates  influx of proton into the infecting virion, 
which facilitates the dissociation of the ribbonucleuproteins from the virion interior and 
allows them to be released into the cytoplasm and transported into the cell nucleus 
(Moscona, 2005). The infected virus is able to attach the cell surface, sialic acid 
containing receptor mediated by HA. On the other hand, virus entry into cells was 
mediated by HA. Indeed, hemagglutinin is the major virulence (disease-causing) factor 
of the influenza virus (Klenk et al., 1977). Hemagglutinin named derives its activity. It 
can stick to, or agglutinate the red blood cells. So far, scientists have found 16 subtypes 
of HA (H1 to H16) but only H1, H2, and H3 sub types of HA are prevalent in human 
infection, while other additional of HAs are important in animal infection (Eisen et al., 
1997; Liu et al., 2009a). 
 
1.2.2.4 Matrix 2 (M2) Proton Channel 
Matrix 2 (M2) of influenza virus is an interesting transmenbrane protein that 
forms tiny proton channel in the viral envelope. M2 ion protein channel is the third 
membrane protein which provides the virus structural integrity by permitting the proton 
to enter virus particle during uncoating of virions in endosome (Bauer et al., 1999.) It is 
a homotetramer consisting of four polypeptide chains of 96 amino acids, with the 
structural domains: an amino-terminal extracellular domain (comprising 23 residues), as 
single internally hydrophobic domain that acts as a transmembrane domain (19 residues) 
and 54-residue cytoplasmic tails. This membrane is important to prevent inactivation of 
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progeny virus as well as premature acid activation of newly synthesized HA which is 
cleaved extracellularly (Betakova, 2007; Rossman et al., 2010). 
 
1.2.3 Transmitting of the Virus 
Like other influenza viruses, the H1N1 viruses may transmit from human to 
human by aerosol route via inhalation of infected droplets from coughing or sneezing or 
through contamination of hands or surface. It can be easily transmitting by air  (Kiely et 
al., 2009). 
 
1.2.4 Treatment of the Virus 
There are two ways to control the virus infection, chemotherapy and vaccination. 
Vaccination is targeting the variable antigenic surface glycoproteins of circulating strain. 
Vaccine is currently available in public health service as a preventive way in high risk 
population. Vaccination can prevent effectively 50% - 68% of acquiring influenza 
infection and minimize the complication and mortality. Vaccine is the best choice for the 
prophylaxis on control the pandemic. However, vaccine is providing very limited 
protection due to specificity of the strain of virus that could be prevented. New vaccine 
is needed annually, due to the rapid change of the virus glycoprotein character (He et al., 
2011; Oxford and Lambkin, 1998). 
 
In short period, chemotherapy using antiviral agent is vital to control the spread 
of the virus. There are only two classes of antiviral licensed globally; adamantane 
derivatives and neuraminidase inhibitor. 
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1.2.4.1 Adamantane Derivatives  
Historycally, the adamantane-based M2 ion channel protein inhibitors are the 
first drugs available for the treatment of influenza. They are amantadine and rimantadine 
which have only been useful in the treatment of Influenza A infection due to only the A 
strains of the virus have M2 ion channel protein (Kiely et al., 2009). The drugs inhibit 
the virus replication by blocking M2 ion channel via its binding at allosteric site which 
triggers a conformational alteration in the pore region. This action causes interfering 
proton transfer during the ion channel across the membrane of the virus or endosome. 
Therefore, the virus is unable to enter the host cell of membrane and the replication is 
blocked (Tisdale, 2009; Sandrock, 2010). 
 
Studies during 1994 to 2005 showed the worldwide increasing of amantadine and 
rimantadine-resistance from 0.4% to 12.3%. New strain of A virus has a resistance to 
amantadine and rimantadine due to the presence of S31N mutation that increase the M2 
protein mobility. The adamantane derivatives have been reported having a poor of 
bioavailability in the human blood. They also have been reported having a side effect on 
gastrointestinal and central nervous system (Rungrotmongkol et al., 2009a). The 
chemical structures of adamantane derivatives were described in Figure 1.4 
 
 
 
 
 
Figure 1.4 Chemical structures of adamantane derivatives (Clercq, 2006) 
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1.2.4.2  Neuraminidase Inhibitor 
Neuraminidase inhibitor is a sialic acid of the surface of human epithelial cells 
compound analogue. The purpose of the inhibition is that the virus will bind to the 
inhibitor instead of the human epithelial cells so the inhibitor-viral complex can be 
removed from the body. The neuraminidase inhibitor has become a drug of choice in 
antiviral drug because of its important role of neuraminidase enzyme. If the enzyme is 
blocked, infection will be limited, and the spread the new virion will be disabled. NA 
has become the primary target for drug design against influenza virus because it is 
responsible toward influenza virus replication in the final cycle of virus‟s life (Wang et 
al., 2006; Wei et al., 2006). 
 
The first NA inhibitor analogue of sialic acid is 2-deoxy-2,3-didehydro-N-
acetylneuraminic acid or Neu5Ac2en (DANA) (Meindl et al., 1974). DANA showed a 
good activity in vitro. However, this compound was non-selective NA inhibitor and did 
not exhibit activity in vivo (Kim et al., 1999).  
 
The discovery of complex 3D structure of NA and DANA, triggered the 
development of more potent anti neuraminidase. In 1993, Mark von Itzsein modified 
DANA by changing the OH in 4 position with guanidinyl group, made 2,4-dideoxy-2,3-
didehydro-4-guanidinosialic acid or 4-guanidino-Neu5Ac2en (zanamivir) (von Itzstein 
et al., 1993). Zanamivir became one of the potent inhibitors which has a structure 
mimicking to sialic acid, fitting into the active site pocket and locking the protein in the 
lowest binding free energy (Moscona, 2005). Zanamivir (or often published as GG167), 
is a selective NA inhibitor which also has activity both in vivo and in vitro. Zanamivir 
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with the brand name Relenza®, due to its high polarity, it was reported to have a poor 
bioavailability in human blood. It was also excreted immediately by the kidneys. Thus, 
Zanamivir has never been advised to use via oral route but only via inhalation. 
Moreover, it is indicated only given for adults and children above 5 years old (Moscona, 
2005). 
 
In 2000, zanamivir structure was added by a lipophylic side chain in C6 position 
in order to increase the bioavailability. This modified compound was named oseltamivir 
(GS 4104) (Lew et al., 2000).  This compound has emerged as a promising antiviral for 
the treatment and prophylaxis of human influenza infection. Oseltamivir acts as prodrug 
(ethyl ester) which is hydrolyzed in vivo to its active form, the carboxylic acid, after 
taken orally. The active form has a poor bioavailability, therefore, oseltamivir is 
prepared in phosphate salt and administered orally (D'Souza, 2009; Hammad and Taha, 
2009). The chemical structure of current neuraminidase inhibitors were presented in 
Figure 1.5.  
 
 
 
 
 
 
Figure 1.5 Chemical structure of neuraminidase inhibitors; DANA, Zanamivir and 
Oseltamivir (Clercq, 2006) 
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So far, only two kinds of neuraminidase inhibitor have been approved by FDA, 
oseltamivir and zanamivir (Lew et al., 2000; Dunn and Goa, 1999). They are active 
against all type of influenza virus, including type A and B influenza virus (Moscona, 
2005). 
 
Lately, new neuraminidase inhibitor, peramivir, an intravenous neuraminidase 
inhibitor has been approved in Japan and Korea. In October 2009, FDA issued an 
Emergency Use Authorization (EUA) which expired in June 2010. The EUA based on 
safety data from Phase 1, Phase 2 trials, and limited Phase 3 trial. Later on, laninamivir, 
a long-acting intranasal neuraminidase inhibitor which has stronger activity than 
zanamivir, has also been licensed for limited use in Japan, even the clinical publications 
were still limited (Kubo et al., 2010; Yamashita, 2011; WHO, 2010c). 
 
However, as the widely used of anti influenza drug and the rapid change of the 
virus genetic, resistant strains of the virus can be expected to develop (Moscona, 2005). 
Oseltamivir with the brand name Tamiflu®, was reported to be resistant on several cases 
of Influenza A infection, and also had side effects such as nausea and vomiting to among 
patients given treatment with this drug (Meindl et al., 1974; Oxford and Lambkin, 
1998). 
 
1.2.5 Antiviral Analysis: Detection of Viral Presence in Samples. 
Since the virus‟s attack was difficult to be detected, scientists tried hard to 
develop the methods to distinguish the efficacy of antiviral substances to limit the viral 
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replication. The general way of detecting the presence of virus in an infected cell is 
using two principal methods: CPE and hemadsorbtion (Knipe and Howley, 2007). 
1. CPE (cytophathic effect), which is composed by two different phenomenon: 
(a) Morphological alterations induced in individual cells or groups of cell by 
viral infection which is identifiable under a light microscope. 
(b) Inclusion, defined the aggregates of stainable substances in biological 
cells. 
2. Hemadsorbtion: refers to the ability of erythrocytes to stick to virus-infected cells. 
Influenza viruses produce cell attachment proteins (HA), which bring out their 
function totally or in part by binding substituent (neuraminic acid) that are plentiful 
on a wide diversity of cell types, including erythrocytes (Knipe and Howley, 2007). 
 
1.2.6 General Methods of Anti-Viral Assay 
Many viruses have distinctive character in their structure and replication cycles. 
Those make them possible to be the potential targets of inhibition. Since virus enzymes 
are essential in viral life for facilitating the viral replication and enhancing disease 
progression, inhibition of the enzymes become the most attractive strategic approach 
(Chattopadhyay et al., 2009).  In influenza virus, common ways to limit the virus 
progression were by inhibiting the host cell binding (hemagglutinin inhibitor), uncoating 
the capsid (adamantine derivatives), DNA or RNA polymerase inhibitor (ribavirin) and 
neuraminidase inhibitor (zanamivir, oseltamivir) (von Itzstein, 2007). The mechanism 
scheme of viral inhibition was described in Figure 1.6. 
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Figure 1.6 Inhibition Mechanism Schematic of Influenza Antiviral 
(Modified from von Itzstein (2007)) 
 
 
1.2.6.1 Hemagglutination Assay 
The first opportunity to prevent influenza virus replication is when the virus 
attaches to the host cell membrane. Influenza virus hemagglutinin oligosaccharides 
attached to the host cell membrane associated with sialic acid terminal position. The 
agents act to inhibit the viral replication by interfering the first attachment step of the 
virus to the host cell, resulting the reducing of HA titre in culture specimen (Cross et al., 
2001).  
 
Hemagglutination assay is different from other forms of virus quantification such 
as a plaque assay or 50% Tissue Culture Infectious Dose (TCID50). This method does 
not give any measure of viral infectivity, because no virus replication is required in this 
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assay. Influenza viruses have envelope surface HA protein that are identified by their 
ability to agglutinate (stick to) human or animal red blood cells (RBC). This activity 
(hemagglutination) can be tested by mixing virus dilutions with RBC in microtitre 
plates. The chosen of RBC depend on the type of influenza virus. H1N1 is more 
sensitive to guinea pig‟s RBC, while H5N1 is more sensitive to chicken‟s erythrocytes. 
For this assay, the guinea pig‟s red blood cell was used (WHO, 2002). If the tested 
compounds or extracts inhibit the virus replication thus the viral titre, HA titre will be 
reduced. This method can be used to examine the inhibitory effect of any drug onto the 
hemagglutination activity (Chattopadhyay et al., 2009). RBCs will form a button or a 
ring at the bottom of the wells and recorded as „-‟. If hemagglutination occurs, that is 
RBCs remain in suspension, it is recorded using a „+‟ symbol. The highest dilution of 
virus that causes complete hemagglutination was considered the endpoint in HA titration 
(WHO, 2002). The titre of a hemagglutination assay is determined by the last viable 
“lattice” or “sand” form. This is because it is at the point where, if diluted anymore, the 
amount of virus particles will be less than that of the RBCs and thus not be able to 
agglutinate them together (Chattopadhyay et al., 2009). So far, only few compounds 
have been tested and showed a good activity to reduce the HA titre, one of those 
compounds is Poloxometalate Derivative (POM-4960) (Hosseini et al., 2012). 
 
Percentage of HA titre reduction:  
HA titre reduction of drug treated virus compare to the untreated (control) virus can be 
performed using this following equation: 
Percentage of reduction = untreated HA titre (control) – treated HA titre  x 100 % 
                                                            untreated HA titre (control)  
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1.2.6.2 Infectious Titre Reduction Assay 
Several methods have been developed to determine antiviral activity. Titre 
reduction assays to determine the efficacy of antiviral candidates is fundamental 
approach used by virologist. In vitro assay using cell lines or cell cultures generally 
exploit the ability of virus to infect and replicate in host cells. It is often performed using 
plaque reduction or cytophatic effect (CPE) reduction on appropriate cell lines in cell 
culture systems. As the development of CPE in this assay was indicating the presence of 
infectious virus, the CPE reduction in presence of test compound could be due to 
inhibition of virus replication. The quantitative statement of the virus titre reduction 
often performed by plaque forming unit (PFU) and TCID50 (Half Tissue Culture 
Infectious Dose). The use of TCID50 can be useful if the plaque was not forming. 
TCID50 is a virus quantifies reflecting an end point dilution which can kill 50 % of cell 
culture or to produce 50% of CPE in infected cell.  Fresh cells are used to evaluate the 
decreasing of infectious virus titre of drug-treated compare to untreated virus by 
measuring CPE induced by these viruses. To assist the investigation, this assay was 
performed by staining of surviving cells after being infected with drug-treated and free-
drug virus in several days of incubation time depending on the type of virus. After 
incubation, the percentage of cell mortality was manually observed. TCID50 was 
calculated using Reed-Muench method. Every method has certain limitation. Skilled 
personnel, cell culture reagents, time consuming and expensive are some of technical 
problems in antiviral assay using titre reduction assay (LaBarre and Lowy, 2001; 
Chattopadhyay et al., 2009). 
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To support the replication of the virus, the appropriate mammalian cell lines 
should be prepared firstly. MDCK cells are the preferred host for the influenza virus. 
Confluent monolayer of MDCK cells need to be prepared prior to the cytotoxity test, 
virus growth inhibition assay and TCID50 assay in tissue culture plates as needed (WHO, 
2002). 
 
In order to obtain the Maximum Non-toxic Dose (MNTD), the cytotoxicity test 
should be performed before proceeding to Viral Growth Inhibition Assay. This assay 
was important to differentiate which activity was caused by the extract or compound 
toxicity to cells or due to the virus activity itself.  Confluent MDCK cell monolayer in 
24 well tissue culture plates (after 2-3 days of incubation in GM) were incubated with 
10-750 µg/mL dilutions of extract and substance in 5 % of DMSO and Maintenance 
Medium. No virus was needed in this experiment. The plates were observed 
microscopically for any morphological changes at 24, 48 and 72 hours of incubation. 
The morphological changes can be granuling, enlargement, rounding and detachment of 
cells from bottom of plates. At the end of incubation day, the medium was removed 
carefully from each wells, the plate was stained with 2% of crystal violet, thus dye was 
took up by healthy and living cells, and the remaining cells were stained in violet. The 
maximum concentration of substances that did not cause any alterations on MDCK in 
the test condition cells was considered as Maximum Non-Toxic Dose (MNTD) 
(Chattopadhyay et al., 2009). 
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1.2.6.3 Neuraminidase Inhibition Assay. 
Inhibitors of neuraminidase have been developed in an effort to prevent the viral 
infection. The inhibitors are structurally similar to the sialic acid on the surface of 
human epithelial cells. The rational hypothesis is that the virus will bind to the inhibitor 
rather than to the human cells, the inhibitor-viral complex can be removed from the 
body, thus the spread of infection can be limited (Oxford and Lambkin, 1998). 
 
It has been well known that the specific one or more enzymatic systems present 
in the body were used by utilizing a small molecule. As the mechanism of enzyme being 
well understood, the drug design targets to enzyme were become highly developed 
resulting in more potent and selective enzyme inhibitors. The removing of N-acetyl 
neuraminic acid (NANA) from sugar chains of glycoproteins by NA is critical for its 
viral activity facilitation to spread of infection to new cells. The inhibition of this viral 
activity can be performed by specific antibodies forms the basis of the neuraminidase-
inhibition (NAI) assay.  
 
A few of neuraminidase assays are currently used for the NAIs assessment. 
Synthetic sialic acid derivatives are commonly used as a substrate for these assays based 
on its cleavage facilitated by NA produce convenient reporting signals for the 
measurement (Pedersen, 2008).  
 
The compound 2‟-(4-methylumbelliferyl)-a-D-acetylneuraminic acid 
(MUNANA) (Figure 1.7) is widely used as a substrate of NA. The cleavage of this 
substrate produces fluorescence which can be detected at 460 nm in emission as well as 
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its excitation at 355 nm. The intensity of fluorescence can reflect the activity of NA 
sensitivity. The calculation of IC50 was done by plotting the percentage of inhibition 
versus the inhibitor concentration and determination of each point was performed in 
triplicate (Zhang et al., 2008). Neuraminidase inhibitory assay performed by enzymatic 
reaction using MUNANA was used in this experiment as described by Portier (1979). 
The activity of NA was measured fluorometrically by determination of the degradation 
product 4-MU from the substrate 4-MUNANA (Potier et al., 1979). 
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Figure 1.7 Chemical structure of 2‟-(4-methylumbelliferyl)-α-D-acetylneuraminic acid 
(MUNANA) 
 
The principle of NA inhibitory assay by using MUNANA as substrate was 
described in Figure 1.8. In this reaction, NA catalyzes the hydrolysis of MUNANA by 
water to get umbeliferone and N-acetyl neuraminic acid (NANA) as products. The 
presence of umbeliferone can be detected by fluorometric method, which is the more 
activity of NA the more quantity of fluorescence absorbtion (Li et al., 2009). 
The inhibition percentage can be counted by using this following equation: 
Inhibition ratio = F enzyme activity control – F test      x 100% 
                            F enzyme control – F blank control  
 
F : fluorescence absorption 
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Figure 1.8 Reaction principle of microplate-based screening assay for NA inhibitors. In 
this reaction, NA catalyzes the hydrolysis of MUNANA by water to get umbeliferone 
and N-acetyl neuraminic acid (NANA) as products. The presence of umbeliferone can 
be detected by fluorometric method (Li et al., 2009) 
  
 
1.3 Molecular Docking 
Docking is a method used for computational studies that attempt to find the 
“best” matching between two molecules: a receptor and a ligand (Halperin et al., 2002). 
It is one of the methods in molecular modelling employed to calculate the bioactive 
conformation of a molecule in the binding site of the protein target. In general, it 
corresponds to find the local minimum of the binding free energy of ligand-protein 
system. Ligand is a tiny particle which interacts with the binding location of protein 
which is recognized as the area corresponding to its biological activity (Kaapro and 
Ojanen, 2002). 
 
One of the docking methods developed by the Scripps Research Institute is 
Autodock 3.0.5 (Morris et al., 1998). In general, steps in docking by using AutoDock 
are divided into: 
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1. Ligand preparation.  
Ligand is assigned with partial atomic charges (gasteiger charges) and the number of 
torsion was calculated. This is then written as pdbq file that recognized by AutoDock . 
 
2. Protein preparation 
For protein preparation, partial atomic charge (kollman charges) is assigned. In addition, 
the protein is also assigned with generalized salvation parameter. The protein structural 
file is then written in pdbqs file recognized by AutoDock.Grid  
 
3 Parameter files preparation. 
The grid parameter file describes the parameter that needed for the AutoGrid program to 
generate grid maps. This includes the location and extent of those maps and specifies 
pair-wise potential energy parameters. Figure 1.9 illustrates the main features of grid 
map. The centre of the grid map is fitted to the ligand, buried inside the active side of the 
protein. The grid spacing is the same in all three dimensions. The macromolecule (i.e 
protein) is embedded in a three-dimensional grid and a probe atom is placed at each grid 
point. The grid point makes a cubical box with 0.375 Å of grid spacing. An affinity grid 
is calculated for each atom type that present in ligand, typically carbon, oxygen, 
hydrogen and nitrogen. The probe atom stored the potential energy due to all the atoms 
in the macromolecule. Figure was taken from the Autodock User’s Guide Version 3.0.5 
 
